-
2024-511990-31-00
5
2022-06-28
Fabry Disease
-
2024-512378-91-00
4
2022-06-24
Unresectable or Advanced Melanoma
-
2023-505635-13-00
5
2022-06-10
Systemic lupus erythematosus
-
2024-513759-34-00
7
2022-05-31
Relapsed or Refractory Acute Leukemias
-
2023-506854-19-00
1
2022-05-19
Solid Tumors
-
2023-507469-24-00
4
2022-04-30
Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodyspl
-
2023-508897-27-00
5
2022-04-28
Multiple Myeloma
-
2024-516914-39-00
5
2022-04-27
Metastatic or unresectable melanoma
-
2023-506359-68-00
5
2022-04-08
Active Proliferative Lupus Nephritis
-
2023-504597-37-00
5
2022-03-25
Focal segmental glomerulosclerosis
-
2023-505696-74-00
5
2022-02-10
systemic lupus erythematosus
-
2024-515902-15-00
4
2022-01-18
Male and female adult patients with locally advanced or metastatic lar
-
2023-503674-20-00
5
2021-12-17
Unresectable, locally advanced, or metastatic Non-Small Cell Lung Canc
-
2023-508248-23-00
5
2021-11-26
Non-alcoholic steatohepatitis (NASH)
-
2024-517965-18-00
4
2021-11-11
Advanced NSCLC with common EGFR-Mutation
-
2023-507342-84-00
5
2021-10-26
Bladder Cancer
-
2023-506926-35-00
5
2021-09-24
Atherosclerotic cardiovascular disease, chronic kidney disease and sys
-
2023-508690-92-00
11
2021-09-20
IgA Nephropathy
-
2023-506368-14-00
5
2021-09-07
Systemic lupus erythematosus (SLE)
-
2023-505850-16-00
5
2021-08-05
Multiple Myeloma
-
2024-516096-32-00
4
2021-08-05
Platinum sensitive recurrent ovarian cancer
-
2024-511321-54-00
5
2021-08-04
intermediate-high-risk acute pulmonary embolism
-
2022-500237-92-00
5
2021-04-23
Newly-diagnosed high-intermediate and high-risk diffuse large B-cell l
-
2023-507961-24-00
5
2021-04-19
High-Risk HER2-Positive Breast Cancer